繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

NRX Pharmaceuticals Secures Non-Binding Debt Financing Agreements for Ketamine Clinics

2024-08-26 21:02

09:02 AM EDT, 08/26/2024 (MT Newswires) -- NRX Pharmaceuticals' (NRXP) HOPE Therapeutics subsidiary said Monday it has signed a non-binding agreement for $30 million in debt financing for its first interventional psychiatric clinics using the drug ketamine.

The company also signed a non-binding agreement for $10 million worth of financing for five existing clinics in the western US.

The company said it has been offered enough financing to build a network of clinics in the US, the UK and France that could generate annual revenue of more than $100 million.

Price: 2.0500, Change: -0.04, Percent Change: -1.91

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。